Foetal Growth Problem
13
0
0
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
62%
8 trials in Phase 3/4
15%
2 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (13)
Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing
Observational Prospective Study on Patients Treated With Norditropin®
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation
Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects
Efficacy on Height in SGA Children Treated With Growth Hormone
Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction
Safety and Efficacy of Long-term Somatropin Treatment in Children
Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone